尼洛替尼治疗中度进展期帕金森病的随机临床试验
这项6个月、多中心、随机双盲安慰剂对照试验在76例中度进展期帕金森病患者中评估尼洛替尼的安全性和耐受性。尼洛替尼150mg和300mg每日一次耐受性可接受,但脑脊液暴露低(脑脊液/血清浓度比0.2%-0.3%),未改变脑脊液多巴胺代谢物,且MDS-UPDRS-3 ON评分在300mg组第1个月显著差于安慰剂(P<.01)。结论认为尼洛替尼不应在帕金森病中进一步测试。
要点
- 尼洛替尼150mg和300mg每日一次在6个月内安全性和耐受性可接受。
- 最常见停药原因为无症状、剂量依赖的淀粉酶和/或脂肪酶升高。
- 尼洛替尼脑脊液/血清浓度比仅0.2%-0.3%,未见脑脊液多巴胺代谢物改变。
核心结论
- 尼洛替尼在中度进展期帕金森病患者中安全性和耐受性可接受,但低脑脊液暴露、缺乏生物标志物效应及疗效数据负向趋势表明其不应在帕金森病中进一步测试。
研究设计与样本
- 筛查125例,纳入76例接受稳定帕金森病药物治疗的患者,按1:1:1随机分配至安慰剂、尼洛替尼150mg或300mg每日一次口服,治疗6个月后停药评估2个月。
- 基线平均(SD)年龄64.6(7.5)岁,男性52例(68%),平均(SD)病程9.9(4.7)年,MDS-UPDRS Part 1-3 OFF评分66.4(19.3),ON评分48.4(16.2),MoCA评分27.1(2.2)。
主要发现
- 完成研究并接受指定剂量的参与者比例在安慰剂组、150mg组和300mg组分别为84%(21例)、76%(19例)和77%(20例)。
- 两个活性剂量安全性特征均可接受,最常见的药物暂停原因为无症状、剂量依赖的淀粉酶和/或脂肪酶升高。
- 尼洛替尼150mg和300mg组MDS-UPDRS-3 ON评分较安慰剂组更差,300mg组在第1个月达到显著性(P<.01)。
- 从基线至6个月MDS-UPDRS-3 OFF评分变化组间无差异(P=.17)。
- 尼洛替尼脑脊液/血清浓度比为0.2%至0.3%,无证据表明治疗相关脑脊液多巴胺代谢物改变。
关键数值与推荐
- 耐受性终点定义为接受指定剂量完成研究的能力;活性组耐受性可接受定义为达到耐受性终点的参与者百分比不显著低于安慰剂组。
- 主要结局为安全性和耐受性;次要结局包括MDS-UPDRS Part II OFF/ON变化;探索性结局包括血清和脑脊液药代动力学及脑脊液多巴胺生物标志物。
临床怎么用
- 尼洛替尼不应在帕金森病中进一步测试或临床使用。
- 对于帕金森病患者的尼洛替尼使用,需关注淀粉酶和脂肪酶的无症状升高。
局限性
- 样本量较小(76例),可能限制统计效能。
- 研究为6个月短期试验,不能评估长期效应。
- 脑脊液/血清浓度比仅0.2%-0.3%,提示中枢渗透有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD). OBJECTIVES: To assess safety and tolerability of nilotinib in participants with moderately advanced PD. Secondary and exploratory objectives were to assess its affect on PD disability, pharmacokinetics, cerebrospinal fluid (CSF) penetration, and biomarkers. DESIGN, SETTING, AND PARTICIPANTS: This was a 6-month, multicenter, randomized parallel-group, double-blind, placebo-controlled trial. Recruitment was from November 20, 2017, to December 28, 2018, and follow-up ended on September 9, 2019. The study was conducted at 25 US sites. The study approached 173 patients, of whom 48 declined, 125 were screened, and 76 who received a stable regimen of PD medications were enrolled (39% screen failure). INTERVENTIONS: Participants were randomized 1:1:1 to placebo, 150-mg nilotinib, or 300-mg nilotinib once daily orally for 6 months, followed by 2-month off-drug evaluation. MAIN OUTCOMES AND MEASURES: The primary outcomes were safety and tolerability. The tolerability end point was defined as the ability to complete the study while receiving the assigned dose. An active arm was considered tolerable if the percentage of participants meeting the tolerability end point for that group was not significantly lower than the percentage observed in the placebo group. Secondary outcomes included change in PD disability (Movement Disorder Society Unified Parkinson's Disease Rating Scale [MDS-UPDRS], Part II OFF/ON). Exploratory outcomes included serum and CSF pharmacokinetic profile, and CSF dopaminergic biomarkers. RESULTS: At baseline, mean (SD) participants' age was 64.6 (7.5) years, 52 were male (68%), mean (SD) disease duration was 9.9 years (4.7), MDS-UPDRS Part 1-3 OFF score was 66.4 (19.3), ON score was 48.4 (16.2), and Montreal Cognitive Assessment score was 27.1 (2.2). The number of participants who completed the study receiving the assigned dose were 21 (84%), 19 (76%), and 20 (77%) in the placebo, 150-mg, and 300-mg arms, respectively. Both active doses had acceptable safety profile. The most common reasons for drug suspension were asymptomatic, dose-dependent elevations of amylase, and/or lipase. Nilotinib, 150 mg and 300 mg, exhibited worse MDS-UPDRS-3 ON scores compared with placebo, achieving significance for nilotinib, 300 mg, at month 1 (P < .01). There was no difference in the change of MDS-UPDRS-3 OFF from baseline to 6 months between groups (P = .17). Cerebrospinal fluid/serum ratio of nilotinib concentration was 0.2% to 0.3%. There was no evidence of treatment-related alteration of dopamine metabolites in the CSF. CONCLUSIONS AND RELEVANCE: While we demonstrated acceptable safety and tolerability of nilotinib in our cohort, the low CSF exposure and lack of biomarkers effect combined with the efficacy data trending in the negative direction indicate that nilotinib should not be further tested in PD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03205488.
引用
- Simuni T, Fiske B, Merchant K, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33315105. doi:10.1001/jamaneurol.2020.4725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。